Israeli company Atox Bio Ltd. has reported a successful clinical trial of its AB103 treatment for Necrotizing Soft-Tissue Infection (NSTI). Financial magazine Globes reports that due to the successful trial, that has shown that the drug was both effective and safe, the company has begun raising millions of dollars. NSTI is a life-threatening bacterial infection with significant morbidity and high mortality rate.
Related posts
EU Awards $5M To Greenhouse Solar Panel Project
February 07, 2023
Israel Builds Super-Advanced Children’s Hospital
February 07, 2023
Two Thirds Of Hi-Tech Workers In Israel Are Men, Study Finds
February 06, 2023
Ancient Crop Is Gene-Edited For Modern Farms
February 06, 2023
Facebook comments